8-K: Damora Therapeutics Changes Independent Auditor

Damora Therapeutics has dismissed EY Denmark and appointed Ernst & Young LLP as its new independent auditor.

Summary

• Damora Therapeutics, Inc. dismissed EY Godkendt Revisionspartnerselskab (EY Denmark) as its independent registered public accounting firm effective April 17, 2026.
• The company simultaneously engaged Ernst & Young LLP (EY US) as its new independent auditor effective April 17, 2026.
• The company reported no disagreements or reportable events with the outgoing auditor during the two most recent fiscal years and the subsequent interim period.
• The outgoing auditor, EY Denmark, confirmed its agreement with the company's disclosures regarding the dismissal.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event; while the change in auditor is routine, the underlying going concern risk remains the primary focus for investors.

Positives

• The transition to a new auditor occurred without any reported disagreements or accounting disputes.
• The outgoing auditor provided a letter confirming agreement with the company's disclosure of the dismissal.

Negatives

• The company's 2024 financial statements included an explanatory paragraph regarding the company's ability to continue as a going concern.

Risks

• The company has previously faced going concern uncertainties, which may persist and require ongoing monitoring by the new auditor.

Future Outlook

No specific forward-looking financial guidance was provided in this filing.

Industry Context

StockSavvy.ai notes that auditor changes are common in the biotech sector, particularly when companies consolidate operations or shift reporting structures to US-based entities, though investors should remain cautious regarding the previously disclosed going concern status.

Comparison to Industry Standards

• The transition between two entities of the same global network (EY Denmark to EY US) is a standard administrative procedure for companies aligning their audit functions with their primary market of operation.

Corporate Governance

Stakeholder Impact

• Shareholders should monitor future filings to see if the new auditor maintains the same going concern assessment as the predecessor.

Next Steps

• The company will proceed with its next financial reporting cycle under the oversight of EY US.

Key Dates

Recommendation

The filing represents a routine administrative change in auditors. Investors should maintain a hold position until further clarity is provided on the company's financial stability and the resolution of the previously noted going concern issues.

Keywords

auditor change, Damora Therapeutics, DMRA, corporate governance, Ernst & Young